Clinical-stage biotech Alterity Therapeutics has appointed internationally recognised neurologist Dr Daniel O Claassen as Chief Medical Advisor as it advances its lead drug candidate ATH434 toward a ...

Multivitamins are the most common dietary supplement in the U.S. People take these pills (or gummies, indeed) for a variety of health reasons, but the science on what multivitamins may do for your ...

Compounds found in cannabis could provide a new roadmap for treating the world’s most common chronic liver disorder, according to a study released by the Hebrew University of Jerusalem.

This stock is making its shareholders smile on Tuesday. Let's find out why. The post Why is this ASX 200 share charging 7% higher today? appeared first on The Motley Fool Australia.

Malignant gliomas are among the deadliest brain cancers, with limited treatment options and poor survival. A new comprehensive review analyzes decades of global clinical data on boron neutron capture ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...

Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026Lorigerlimab Phase 2 LINNET study update in mid-2026IND ...

Positive data from EXPERTS-ALS could accelerate RT1999 towards a registration trial; RT1999 to be presented as a poster ...

Scientists at Brigham and Women’s Hospital and others studied thousands of older adults who were asked to take a daily multivitamin and multimineral supplement. They found evidence that daily ...

New platform connects patients with licensed providers offering sermorelin under medical supervision, supported by a growing body of peer-reviewed research and an emerging community of clinicians and ...

Based on the clinical trial findings, Ipsen is withdrawing Tazverik across all indications, including both follicular lymphoma and epithelioid sarcoma, and is discontinuing all active tazemetostat ...